Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases

被引:419
作者
Aloia, Thomas
Sebagh, Mylene
Plasse, Marylene
Karam, Vincent
Levi, Francis
Giacchetti, Sylvie
Azoulay, Daniel
Bismuth, Henri
Castaing, Denis
Adam, Rene
机构
[1] Hop Paul Brousse, Dept Hepatobiliary Surg & Liver Transplantat, F-94800 Villejuif, France
[2] Hop Paul Brousse, Dept Pathol, F-94800 Villejuif, France
[3] Hop Paul Brousse, INSERM, Chronotherapy Unit, F-94800 Villejuif, France
[4] Hop St Luc, Dept Hepatobiliary Surg & Liver Transplantat, Montreal, PQ H2X 1P1, Canada
关键词
D O I
10.1200/JCO.2006.05.8156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Preoperative chemotherapy for colorectal liver metastases (CLM) can produce histologic changes in the nontumor-bearing liver (NTBL) that may impact on surgical outcomes. Patients and Methods From a cohort of 303 patients treated for CLM with liver resection, 92 patients ( 75 received preoperative chemotherapy: group C+; and 17 were chemotherapy naive: group C -) were randomly selected for detailed pathologic analysis. Preoperative chemotherapy consisted of fluorouracil (FU)/ leucovorin alone ( 23 patients, the majority chronomodulated) or in combination with oxaliplatin ( 52 patients, all chronomodulated). To determine associations between study factors, clinical and operative variables were compared with pathology data and surgical outcomes. Results Although clinical and operative factors were similarly distributed, C+ patients, compared with C- patients, were more likely to receive intraoperative RBC transfusions ( mean units: 1.9 v 0.5, respectively; P =.03) and to have vascular abnormalities in the NTBL (52% v 18%, respectively; P =.01). Presence of the most severe forms of vascular alterations was closely associated with RBC transfusion requirements ( P =.04). In contrast, moderate to severe steatosis was similarly distributed ( C - group, 12%; C + group, 13%). Although perioperative mortality and morbidity rates were similar in all groups, more than 12 courses of chemotherapy, compared with <= 12 courses, predisposed patients to reoperation (11% v 0%, respectively; P =.04) and to longer hospitalization ( 15 v 11 days, respectively; P =.02). Conclusion The main hepatic lesion induced by preoperative FU/oxaliplatin chemotherapy in patients with CLM is vascular and not steatosis. Detailed pathologic analysis determined that the most severe vascular lesions are associated with increased intraoperative transfusions. The risk for other postoperative complications is related to the duration of preoperative chemotherapy administration.
引用
收藏
页码:4983 / 4990
页数:8
相关论文
共 23 条
  • [1] Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
  • [2] Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
  • [3] Re: Pooled analysis of fluorouracil-based adjuvant therapy of stage II and III colon cancer: Who benefits and by how much? Reply
    Alberts, SR
    Sargent, DJ
    Gill, S
    Loprinzi, CL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 654 - 655
  • [4] Hepatic Steatosis as a Potential Risk Factor for Major Hepatic Resection
    Behrns K.E.
    Tsiotos G.G.
    DeSouza N.F.
    Krishna M.K.
    Ludwig J.
    Nagorney D.M.
    [J]. Journal of Gastrointestinal Surgery, 1998, 2 (3) : 292 - 298
  • [5] Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection
    Belghiti, J
    Hiramatsu, K
    Benoist, S
    Massault, PP
    Sauvanet, A
    Farges, O
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 191 (01) : 38 - 46
  • [6] Trends in long-term survival following liver resection for hepatic colorectal metastases
    Choti, MA
    Sitzmann, JV
    Tiburi, MF
    Sumetchotimetha, W
    Rangsin, R
    Schulick, RD
    Lillemoe, KD
    Yeo, CJ
    Cameron, JL
    [J]. ANNALS OF SURGERY, 2002, 235 (06) : 759 - 765
  • [7] ELIAS D, 1995, J AM COLL SURGEONS, V180, P213
  • [8] Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)
    Fernandez, FG
    Drebin, JA
    Linehan, DC
    Dehdashti, F
    Siegel, BA
    Strasberg, SM
    [J]. ANNALS OF SURGERY, 2004, 240 (03) : 438 - 447
  • [9] Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
    Giacchetti, S
    Perpoint, B
    Zidani, R
    Le Bail, N
    Faggiuolo, R
    Focan, C
    Chollet, P
    Llory, JF
    Letourneau, Y
    Coudert, B
    Bertheaut-Cvitkovic, F
    Larregain-Fournier, D
    Le Rol, A
    Walter, S
    Adam, R
    Misset, JL
    Lévi, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 136 - 147
  • [10] Pringle's manoeuvre in living donors
    Imamura, H
    Takayama, T
    Sugawara, Y
    Kokudo, N
    Aoki, T
    Kaneko, J
    Matsuyama, Y
    Sano, K
    Maema, A
    Makuuchi, M
    [J]. LANCET, 2002, 360 (9350) : 2049 - 2050